Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Heidenreich, S; Ziagkos, D; de Wreede, LC; van Biezen, A; Finke, J; Platzbecker, U; Niederwieser, D; Einsele, H; Bethge, W; Schleuning, M; Beelen, DW; Tischer, J; Nagler, A; Glass, B; Maertens, J; Yáñez, L; Beguin, Y; Sill, H; Scheid, C; Stelljes, M; Ganser, A; Zachée, P; Selleslag, D; de Witte, T; Robin, M; Kröger, N.
Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.
Biol Blood Marrow Transplant. 2017; 23(1):44-52
Doi: 10.1016/j.bbmt.2016.09.027
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Sill Heinz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- In this retrospective analysis we evaluated the outcome of 313 patients aged ≥ 70 years in the registry of the European Group for Blood and Marrow Transplantation with myelodysplastic syndrome (MDS; n = 221) and secondary acute myeloid leukemia (n = 92) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) from related (n = 79) or unrelated (n = 234) donors. Median age at HSCT was 72 years (range, 70 to 78). Conditioning regimen was nonmyeloablative (n = 54), reduced intensity (n = 207), or standard intensity (n = 52). Allogeneic HSCT for MDS patients ≥ 70 years was increasingly performed over time. Although during 2000 to 2004 only 16 patients received HSCT, during 2011 to 2013 the number of transplantations increased to 181. The cumulative incidence of nonrelapse mortality at 1 year and relapse at 3 years was 32% and 28%, respectively, with a 3-year overall survival rate of 34%. Good performance, determined by Karnofsky performance status, and recipients' seronegativity for cytomegalovirus was associated with 3-year estimated overall survival rates of 43% (P = .01) and 46% (P = .002), respectively. Conditioning intensity did not impact survival. After careful patient selection, allogeneic HSCT can be offered to patients older than 70 years with MDS. Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Cytomegalovirus - immunology
- Europe -
- Female -
- Hematopoietic Stem Cell Transplantation - methods
- Hematopoietic Stem Cell Transplantation - mortality
- Humans -
- Karnofsky Performance Status -
- Leukemia, Myeloid, Acute - mortality
- Leukemia, Myeloid, Acute - therapy
- Male -
- Myelodysplastic Syndromes - mortality
- Myelodysplastic Syndromes - therapy
- Recurrence -
- Registries -
- Retrospective Studies -
- Survival Analysis -
- Tissue Donors -
- Transplantation Conditioning - methods
- Transplantation Conditioning - mortality
- Transplantation, Homologous -
- Find related publications in this database (Keywords)
- Myelodysplastic syndrome
- MDS
- Acute myeloid leukemia
- AML
- Karnofsky performance status
- CMV
- HSCT
- EBMT
- Age